MultiHance (gadobenate dimeglumine) is indicated for intravenous use in MRI of the CNS in adults to visualize lesions with abnormal blood brain barrier or abnormal vascularity of the brain, spine, and associated tissues.
MultiHance is a Magnetic Resonance Imaging (MRI) contrast agent that has nearly twice the relaxtivity of other gadolinium-based contrast agents providing a marked increase in Signal-to-Noise Ratio (SNR) in T1-weighted images. Unlike other paramagnetic contrast agents, MultiHance reportedly demonstrates weak and transient interactions with serum proteins that causes slowing in the molecular tumbling dynamics, resulting in strong increases in relaxivity in solutions containing serum proteins. The improved relaxation effect could potentially contribute to improved visualization.
Bracco launched MultiHance in Europe in 1998 and received FDA approval to market in the US in 2004, with over 3.5 million doses used worldwide.
April 18, 2024 
